BR112014000268A2 - pirazolopiridinas com substituinte heteroarilo e utilização destas - Google Patents

pirazolopiridinas com substituinte heteroarilo e utilização destas

Info

Publication number
BR112014000268A2
BR112014000268A2 BR112014000268A BR112014000268A BR112014000268A2 BR 112014000268 A2 BR112014000268 A2 BR 112014000268A2 BR 112014000268 A BR112014000268 A BR 112014000268A BR 112014000268 A BR112014000268 A BR 112014000268A BR 112014000268 A2 BR112014000268 A2 BR 112014000268A2
Authority
BR
Brazil
Prior art keywords
pyrazolopyridines
treatment
prophylaxis
heteroaryl substituent
heteroaryl substituted
Prior art date
Application number
BR112014000268A
Other languages
English (en)
Inventor
Lang Dieter
Wunder Frank
Redlich Gorden
Stasch Johannes-Peter
Follmann Markus
Griebenow Nils
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201110078715 external-priority patent/DE102011078715A1/de
Priority claimed from DE201210200354 external-priority patent/DE102012200354A1/de
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112014000268A2 publication Critical patent/BR112014000268A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

resumo da patente de invenção para: “pirazolopiridinas com substituinte heteroarilo e utilização destas”. o presente pedido de patente refere-se a novas pirazolopiridinas com substituinte heteroarilo, aos processos para a preparação destas, à utilização destas isoladamente ou em combinações para o tratamento e/ou profilaxia de doenças e à utilização destas na produção de medicamentos destinados ao tratamento e/ou profilaxia de doenças, em particular para o tratamento e/ou profilaxia de doenças cardiovasculares. 1/1
BR112014000268A 2011-07-06 2012-07-05 pirazolopiridinas com substituinte heteroarilo e utilização destas BR112014000268A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE201110078715 DE102011078715A1 (de) 2011-07-06 2011-07-06 Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
DE201210200354 DE102012200354A1 (de) 2012-01-11 2012-01-11 Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
PCT/EP2012/063155 WO2013004785A1 (de) 2011-07-06 2012-07-05 Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase

Publications (1)

Publication Number Publication Date
BR112014000268A2 true BR112014000268A2 (pt) 2017-04-25

Family

ID=46508330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000268A BR112014000268A2 (pt) 2011-07-06 2012-07-05 pirazolopiridinas com substituinte heteroarilo e utilização destas

Country Status (13)

Country Link
US (1) US20140228366A1 (pt)
EP (1) EP2729476B1 (pt)
JP (1) JP6109161B2 (pt)
KR (1) KR20140050029A (pt)
CN (1) CN103906752B (pt)
AU (1) AU2012280246A1 (pt)
BR (1) BR112014000268A2 (pt)
CA (1) CA2840886A1 (pt)
ES (1) ES2648810T3 (pt)
MX (1) MX2014000029A (pt)
RU (1) RU2014103960A (pt)
WO (1) WO2013004785A1 (pt)
ZA (1) ZA201400050B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2504334T1 (sl) 2009-11-27 2014-11-28 Bayer Intellectual Property Gmbh Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
WO2012143510A1 (de) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
JP6054967B2 (ja) * 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アネレート化ピリミジンおよびその使用
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
CA2866213A1 (en) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituted azabicycles and use thereof
MX2015006856A (es) 2012-11-30 2016-02-17 Astellas Pharma Inc Compuestos imidazopiridina.
WO2014131760A1 (de) * 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
CN105026405B (zh) * 2013-03-01 2017-08-08 拜耳制药股份公司 苄基‑取代的吡唑并吡啶及其用途
KR20160030541A (ko) 2013-07-10 2016-03-18 바이엘 파마 악티엔게젤샤프트 벤질-1H-피라졸로[3,4-b]피리딘 및 그의 용도
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN106304835A (zh) 2013-12-11 2017-01-04 铁木医药有限公司 sGC刺激剂
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016030362A1 (de) 2014-08-29 2016-03-03 Bayer Pharma Aktiengesellschaft Substituierte annellierte pyrimidine und ihre verwendung
CN107074883A (zh) * 2014-08-29 2017-08-18 拜耳医药股份有限公司 氨基取代的环状嘧啶及其用途
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
BR112017023855A2 (pt) 2015-05-06 2018-07-17 Bayer Pharma Aktiengesellschaft o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
HUE052337T2 (hu) 2015-07-23 2021-04-28 Bayer Pharma AG Oldható guanilát-cikláz stimulátorai/aktivátorai a neutrális endopeptidáz egy inhibitorával (NEP-inhibitor) és/vagy egy angiotenzin All-antagonistával kombinációban és ezek alkalmazása
MX2018007152A (es) 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
CN106560180A (zh) * 2016-05-24 2017-04-12 聊城市奥润生物医药科技有限公司 鸟嘌呤核糖苷-3′,5′-环磷酸酯（cGMP）在制备抗肺动脉高压及慢性阻塞性肺病药物中的应用
JP7237823B2 (ja) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ
CN110022871A (zh) 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
AU2019269047A1 (en) 2018-05-15 2020-11-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
KR20210031931A (ko) 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
US20230257398A1 (en) * 2020-04-30 2023-08-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrimidine-based tricyclic compound and use thereof
MX2024004273A (es) * 2021-10-13 2024-04-25 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado triciclico de pirimidina y aplicacion farmaceutica del mismo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
PL332871A1 (en) * 1996-10-14 1999-10-25 Bayer Ag Novel heterocyclylmethyl-substituted derivative of pyrazole
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
WO2002042299A1 (de) * 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue lactam-substituierte pyrazolopyridinderivate
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1626045B1 (en) 2003-05-09 2010-09-08 Asahi Glass Company, Limited Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof
CN100355732C (zh) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 2－氯－5－氟－烟酸酯及酸的制备方法
DE102005031576A1 (de) * 2005-07-06 2007-01-25 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden
JP5553751B2 (ja) 2007-07-31 2014-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ５−フルオロ−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−アミンおよびその誘導体を調製するためのプロセス
JP5501369B2 (ja) * 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
US9040538B2 (en) 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
MA34330B1 (fr) * 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble

Also Published As

Publication number Publication date
AU2012280246A1 (en) 2014-01-23
CA2840886A1 (en) 2013-01-10
JP6109161B2 (ja) 2017-04-05
MX2014000029A (es) 2014-02-17
CN103906752A (zh) 2014-07-02
KR20140050029A (ko) 2014-04-28
JP2014523895A (ja) 2014-09-18
ZA201400050B (en) 2015-04-29
CN103906752B (zh) 2016-08-24
ES2648810T3 (es) 2018-01-08
US20140228366A1 (en) 2014-08-14
RU2014103960A (ru) 2015-08-20
WO2013004785A1 (de) 2013-01-10
EP2729476A1 (de) 2014-05-14
EP2729476B1 (de) 2017-08-23

Similar Documents

Publication Publication Date Title
BR112014000268A2 (pt) pirazolopiridinas com substituinte heteroarilo e utilização destas
BR112014016971A2 (pt) pirimidinas e triazinas fundidas substituídas e seus usos
BR122020008544B8 (pt) uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento
BR112015010072A2 (pt) imizado[1,2-a]piridinacarboxamidas substituídas com amino e sua utilização
BR112014005110A2 (pt) pirimidinas aneladas substituídas e utilização das mesmas
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112015014800A2 (pt) derivados da exendina-4 funcionalizada
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015024678A2 (pt) inibidor da cinase
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
BR112013031485A2 (pt) "anticorpos anti-psl de pseudomonas, seus método de produção e uso na prevenção ou no tratamento de infecção por pseudomonas, polinucleotídeo, 5 vetor, composição farmacêutica, bem como métodos in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais e para aumento de morte opsonofagocítica de p. aeruginosa"
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112016023554A2 (pt) novos compostos macrocíclicos
BR112014018767A8 (pt) Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
IN2012DN00239A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]